260 related articles for article (PubMed ID: 37210568)
21. Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses.
Lee JM; Hays JL; Annunziata CM; Noonan AM; Minasian L; Zujewski JA; Yu M; Gordon N; Ji J; Sissung TM; Figg WD; Azad N; Wood BJ; Doroshow J; Kohn EC
J Natl Cancer Inst; 2014 Jun; 106(6):dju089. PubMed ID: 24842883
[TBL] [Abstract][Full Text] [Related]
22. The PARP inhibitor AZD2281 (Olaparib) induces autophagy/mitophagy in BRCA1 and BRCA2 mutant breast cancer cells.
Arun B; Akar U; Gutierrez-Barrera AM; Hortobagyi GN; Ozpolat B
Int J Oncol; 2015 Jul; 47(1):262-8. PubMed ID: 25975349
[TBL] [Abstract][Full Text] [Related]
23. Hematologic toxicities of chemotherapy in breast and ovarian cancer patients carrying BRCA1/BRCA2 germline pathogenic variants. A single center experience and review of the literature.
Hu-Heimgartner K; Lang N; Ayme A; Ming C; Combes JD; Chappuis VN; Vazquez C; Friedlaender A; Vuilleumier A; Bodmer A; Viassolo V; Sandoval JL; Chappuis PO; Labidi-Galy SI
Fam Cancer; 2023 Jul; 22(3):283-289. PubMed ID: 37119509
[TBL] [Abstract][Full Text] [Related]
24. Clinicopathological characteristics and eligibility for adjuvant olaparib of germline BRCA1/2 mutation carriers with HER2-negative early breast cancer.
Morganti S; Jin Q; Vincuilla J; Buehler R; Ryan S; Stokes S; Parker T; Mittendorf EA; King TA; Weiss A; Partridge AH; Bychkovsky BL; Curigliano G; Tayob N; Lin NU; Garber JE; Tolaney SM; Lynce F
NPJ Breast Cancer; 2024 Apr; 10(1):28. PubMed ID: 38627457
[TBL] [Abstract][Full Text] [Related]
25. Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer.
Rafii S; Gourley C; Kumar R; Geuna E; Ern Ang J; Rye T; Chen LM; Shapira-Frommer R; Friedlander M; Matulonis U; De Greve J; Oza AM; Banerjee S; Molife LR; Gore ME; Kaye SB; Yap TA
Oncotarget; 2017 Jul; 8(29):47154-47160. PubMed ID: 28454085
[TBL] [Abstract][Full Text] [Related]
26. Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial.
Banerjee S; Moore KN; Colombo N; Scambia G; Kim BG; Oaknin A; Friedlander M; Lisyanskaya A; Floquet A; Leary A; Sonke GS; Gourley C; Oza A; González-Martín A; Aghajanian C; Bradley WH; Holmes E; Lowe ES; DiSilvestro P
Lancet Oncol; 2021 Dec; 22(12):1721-1731. PubMed ID: 34715071
[TBL] [Abstract][Full Text] [Related]
27. Clinical Considerations for the Integration of Adjuvant Olaparib into Practice for Early Breast Cancer: A Canadian Perspective.
Henning JW; Boileau JF; Peck L; McFarlane T
Curr Oncol; 2023 Aug; 30(8):7672-7691. PubMed ID: 37623037
[TBL] [Abstract][Full Text] [Related]
28. OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer.
Robson ME; Im SA; Senkus E; Xu B; Domchek SM; Masuda N; Delaloge S; Tung N; Armstrong A; Dymond M; Fielding A; Allen A; Conte P
Eur J Cancer; 2023 May; 184():39-47. PubMed ID: 36893711
[TBL] [Abstract][Full Text] [Related]
29. Toxicity of (neo)adjuvant chemotherapy for BRCA1- and BRCA2-associated breast cancer.
Drooger JC; Heemskerk-Gerritsen BAM; Smallenbroek N; Epskamp C; Seynaeve CM; Jager A
Breast Cancer Res Treat; 2016 Apr; 156(3):557-566. PubMed ID: 27060914
[TBL] [Abstract][Full Text] [Related]
30. Olaparib monotherapy for Asian patients with a germline BRCA mutation and HER2-negative metastatic breast cancer: OlympiAD randomized trial subgroup analysis.
Im SA; Xu B; Li W; Robson M; Ouyang Q; Yeh DC; Iwata H; Park YH; Sohn JH; Tseng LM; Goessl C; Wu W; Masuda N
Sci Rep; 2020 May; 10(1):8753. PubMed ID: 32472001
[TBL] [Abstract][Full Text] [Related]
31. Cost-Effectiveness Analysis of Adjuvant Olaparib Versus Watch and Wait in the Treatment of Germline BRCA1/2-Mutated, High-Risk, HER2-Negative Early Breast Cancer in Sweden.
Polyzoi M; Ekman M; Reithmeier A; Jacob J; Karlsson E; Bertranou E; Linderholm B; Hettle R
Pharmacoecon Open; 2024 Mar; 8(2):277-289. PubMed ID: 38093030
[TBL] [Abstract][Full Text] [Related]
32. Olaparib as maintenance therapy in patients with BRCA 1-2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome.
Cecere SC; Giannone G; Salutari V; Arenare L; Lorusso D; Ronzino G; Lauria R; Cormio G; Carella C; Scollo P; Ghizzoni V; Raspagliesi F; Di Napoli M; Mazzoni E; Marchetti C; Bergamini A; Orditura M; Valabrega G; Scambia G; Maltese G; De Matteis E; Cardalesi C; Loizzi V; Boccia S; Naglieri E; Scandurra G; Pignata S
Gynecol Oncol; 2020 Jan; 156(1):38-44. PubMed ID: 31699415
[TBL] [Abstract][Full Text] [Related]
33. Targeting the molecular defect in BRCA-deficient tumors for cancer therapy.
Venkitaraman AR
Cancer Cell; 2009 Aug; 16(2):89-90. PubMed ID: 19647219
[TBL] [Abstract][Full Text] [Related]
34. Germline BRCA1/2 mutations and severe haematological toxicities in patients with breast cancer treated with neoadjuvant chemotherapy.
Furlanetto J; Möbus V; Schneeweiss A; Rhiem K; Tesch H; Blohmer JU; Lübbe K; Untch M; Salat C; Huober J; Klare P; Schmutzler R; Couch FJ; Lederer B; Gerber B; Zahm DM; Bauerfeind I; Nekljudova V; Hanusch C; Jackisch C; Link T; Hahnen E; Loibl S; Fasching PA
Eur J Cancer; 2021 Mar; 145():44-52. PubMed ID: 33423006
[TBL] [Abstract][Full Text] [Related]
35. Adjuvant versus neoadjuvant chemotherapy in triple-negative breast cancer patients with BRCA mutations.
Clifton K; Gutierrez-Barrera A; Ma J; Bassett R; Litton J; Kuerer H; Moulder S; Albarracin C; Hortobagyi G; Arun B
Breast Cancer Res Treat; 2018 Jul; 170(1):101-109. PubMed ID: 29470805
[TBL] [Abstract][Full Text] [Related]
36. The role of novel poly (ADP-ribose) inhibitors in the treatment of locally advanced and metastatic Her-2/neu negative breast cancer with inherited germline BRCA1/2 mutations. A review of the literature.
Pop L; Suciu I; Ionescu O; Bacalbasa N; Ionescu P
J Med Life; 2021; 14(1):17-20. PubMed ID: 33767780
[TBL] [Abstract][Full Text] [Related]
37. A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline
Turner NC; Telli ML; Rugo HS; Mailliez A; Ettl J; Grischke EM; Mina LA; Balmaña J; Fasching PA; Hurvitz SA; Wardley AM; Chappey C; Hannah AL; Robson ME;
Clin Cancer Res; 2019 May; 25(9):2717-2724. PubMed ID: 30563931
[TBL] [Abstract][Full Text] [Related]
38. Is there any association between acute kidney injury and olaparib use in patients with BRCA1- or BRCA2-mutated high-risk early breast cancer from the phase 3 OlympiA trial.
Altundag K
Breast Cancer; 2023 Nov; 30(6):1107. PubMed ID: 37166624
[No Abstract] [Full Text] [Related]
39. Indirect treatment comparison of olaparib and talazoparib in germline BRCA-mutated HER2-negative metastatic breast cancer.
McCrea C; Hettle R; Gulati P; Taneja A; Rajora P
J Comp Eff Res; 2021 Sep; 10(13):1021-1030. PubMed ID: 34231369
[No Abstract] [Full Text] [Related]
40. PARP Inhibitors in the Treatment of Early Breast Cancer: The Step Beyond?
Gonçalves A; Bertucci A; Bertucci F
Cancers (Basel); 2020 May; 12(6):. PubMed ID: 32471249
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]